Inhibition of GABA(A) receptor (GABAR) currents by arachidonic acid in HEK 293 cells stably transfected with alpha1beta2gamma2 GABAR subunits.
Agonist-stimulated liberation of arachidonic acid and subsequent generation of active metabolites are established components of several signal transduction pathways including pathways that regulate ion channels. We evaluated the role of arachidonic acid and some related unsaturated and saturated fatty acids in the modulation of a stably expressed recombinant gamma-aminobutyric acidA receptor (GABAR) isoform, the alpha1beta2gamma2 isoform. Whole-cell currents evoked by 10 microM GABA were inhibited in a concentration-dependent manner by arachidonic acid (0.1-100 microM). This effect of arachidonic acid to inhibit GABAR currents was not reproduced by the non-metabolizable analog of arachidonic acid, 5,8,11,14-eicosatetraynoic acid (ETYA) or by other monounsaturated or saturated fatty acids. However, another polyunsaturated fatty acid, linoleic acid, which is an essential fatty acid and an effective reductant like arachidonic acid, inhibited GABAR currents in a manner similar to arachidonic acid. Nordihydroguaiaretic acid (NDGA), indomethacin and 1-amonibenzotriazole (1-ABT) did not block the inhibitory effect of arachidonic acid, suggesting that arachidonic acid metabolites of the lipoxygenase, cyclooxygenase or P-450 pathways are unlikely to play a major role in the inhibitory effect of arachidonic acid on GABAR currents. However, the antioxidant N-acetyl cysteine (NAC), a scavenger of active oxygen radicals, reduced the inhibitory effect of arachidonic acid on GABAR currents significantly (P<0.01), suggesting that active oxygen radicals might mediate inhibition of GABAR currents by arachidonic acid.
Saxena
N C
NC
Center for Cell and Molecular Signaling and Department of Physiology, Emory University, Atlanta, GA 30322, USA. nsaxena@ccms-renal.physio.emory.edu
D015117:5,8,11,14-Eicosatetraynoic Acid / Q000494:pharmacology; D000927:Anticonvulsants / Q000494:pharmacology; D016718:Arachidonic Acid / Q000494:pharmacology*; D001667:Binding, Competitive; D002478:Cells, Cultured; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D003975:Diazepam / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005227:Fatty Acids / Q000494:pharmacology; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D018757:GABA Modulators / Q000494:pharmacology; D058787:GABA-A Receptor Antagonists; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology; D007668:Kidney / Q000166:cytology; D019787:Linoleic Acid / Q000494:pharmacology; D009637:Masoprocol / Q000494:pharmacology; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D018408:Patch-Clamp Techniques; D010424:Pentobarbital / Q000494:pharmacology; D010852:Picrotoxin / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000235:genetics; D014162:Transfection; D014230:Triazoles / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
D015117:5,8,11,14-Eicosatetraynoic Acid; D000927:Anticonvulsants; D016718:Arachidonic Acid; D016861:Cyclooxygenase Inhibitors; D003975:Diazepam; D005227:Fatty Acids; D005229:Fatty Acids, Monounsaturated; D018756:GABA Antagonists; D018757:GABA Modulators; D058787:GABA-A Receptor Antagonists; D007213:Indomethacin; D019787:Linoleic Acid; D009637:Masoprocol; D010424:Pentobarbital; D010852:Picrotoxin; D011963:Receptors, GABA-A; D011994:Recombinant Proteins; D014230:Triazoles; D005680:gamma-Aminobutyric Acid; C033020:1-aminobenzotriazole; C066440:loreclezole